Leuprolide

Generic Name
Leuprolide
Brand Names
Camcevi, Eligard, Fensolvi, Lupaneta Pack 1-month, Lupron, Lupron Depot-ped, Viadur, Zeulide Depot
Drug Type
Small Molecule
Chemical Formula
C59H84N16O12
CAS Number
53714-56-0
Unique Ingredient Identifier
EFY6W0M8TG
Background

Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the...

Indication

Leuprolide is indicated for the treatment of advanced prostate cancer and as palliative treatment of advanced prostate cancer.

It is also used for the treatment of pediatric patients with central precocious puberty (CPP).
...

Associated Conditions
Advanced Prostate Cancer, Anemia, Central Precocious Puberty (CPP), Endometriosis
Associated Therapies
Palliative Treatment
Clinical Trials
Related News

Treatment of Hot Flushes Caused by Leuprorelin 11.25 mg in Prostate Adenocarcinoma

First Posted Date
2009-11-11
Last Posted Date
2015-07-30
Lead Sponsor
Takeda
Target Recruit Count
311
Registration Number
NCT01011751
Locations
🇫🇷

Professor Jacques IRANI, Poitiers, France

A Study of Degarelix in Patients With Prostate Cancer

Phase 3
Completed
Conditions
Prostate Cancer
Interventions
Drug: Degarelix
Drug: Leuprolide
First Posted Date
2009-06-26
Last Posted Date
2016-12-13
Lead Sponsor
Ferring Pharmaceuticals
Target Recruit Count
409
Registration Number
NCT00928434
Locations
🇺🇸

Southeastern Urology Center, PA, Tallahassee, Florida, United States

🇺🇸

Chesapeake Urology Associates, Baltimore, Maryland, United States

🇺🇸

Urology Associates Research, Englewood, Colorado, United States

and more 55 locations

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone Acetate in Male Participants With Prostate Cancer

First Posted Date
2009-06-19
Last Posted Date
2013-04-17
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
58
Registration Number
NCT00924469

Extended Endocrine Therapy for Premenopausal Women With Breast Cancer

First Posted Date
2009-05-18
Last Posted Date
2016-04-18
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
17
Registration Number
NCT00903162
Locations
🇺🇸

University of Colorado, Denver, Colorado, United States

🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

Newton Wellesley Hospital, Newton, Massachusetts, United States

and more 1 locations

Intermittent Hormonal Therapy With Leuprorelin and Flutamide in the Treatment of Stage D2 or TxNxM1b,c

Phase 2
Completed
Conditions
Prostatic Neoplasms
Interventions
Drug: Leuprorelin
Drug: Flutamide
First Posted Date
2009-01-06
Last Posted Date
2015-07-29
Lead Sponsor
Takeda
Target Recruit Count
341
Registration Number
NCT00817739

PGL4001 Versus GnRH-agonist in Uterine Myomas

Phase 3
Completed
Conditions
Uterine Myomas
Interventions
Drug: PGL4001
Drug: leuprorelin
First Posted Date
2008-08-25
Last Posted Date
2012-12-17
Lead Sponsor
PregLem SA
Target Recruit Count
301
Registration Number
NCT00740831
Locations
🇪🇸

Hospital Universitario Vall d'Hebrón, Barcelona, Spain

🇮🇹

Clinica Obstetrica - Azienda Ospedaliera Universitaria di Cagliari, Cagliari, Italy

🇮🇹

Policlinico Universitario Federico II, Napoli, Italy

and more 41 locations

Sunitinib Malate, Hormone Ablation and Radiation Therapy in Patients With Prostate Cancer

First Posted Date
2008-03-07
Last Posted Date
2015-01-29
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
19
Registration Number
NCT00631527
Locations
🇺🇸

University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Comparison of Two Pharmacological Treatments of Pedophilia

Phase 3
Terminated
Conditions
Pedophilia
Interventions
Drug: leuprorelin
Drug: Cyproterone acetate
First Posted Date
2008-01-28
Last Posted Date
2009-07-13
Lead Sponsor
Institut National de la Santé Et de la Recherche Médicale, France
Target Recruit Count
48
Registration Number
NCT00601276
Locations
🇫🇷

Federation d'Endocrinologie, Hopital NeuroCardiologique, Bron, France

🇫🇷

Centre MédicoPsychologique CMPG21, EPS Perray Vaucluse, Paris, France

🇫🇷

Service de Psychiatrie, Hopital Foch, Suresnes, France

and more 1 locations

Study of Abraxane Plus Hormonal Therapy as Initial Treatment of Unresectable or Metastatic Prostate Cancer

First Posted Date
2007-08-28
Last Posted Date
2016-03-17
Lead Sponsor
The Methodist Hospital Research Institute
Target Recruit Count
14
Registration Number
NCT00521781
Locations
🇺🇸

Baylor College of Medicine - Methodist Hospital, Houston, Texas, United States

A Study of Androgen Deprivation With Leuprolide, +/- Docetaxel for Clinically Asymptomatic Prostate Cancer Participants With a Rising Prostate Specific Antigen (PSA)

First Posted Date
2007-08-10
Last Posted Date
2013-11-03
Lead Sponsor
Sanofi
Target Recruit Count
413
Registration Number
NCT00514917
Locations
🇪🇸

Sanofi-Aventis Administrative Office, Barcelona, Spain

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy